Vivos Therapeutics, Inc. (VVOS) intrinsic value & 10-year financials
Vivos Therapeutics, Inc. (VVOS) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 8 fiscal years revenue grew 7.4% a year to $17.4M, with an average return on invested capital of -844.0%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.13
- Market cap
- $1.3M
- Revenue (FY2025)
- $17.4M
- Revenue growth (8-yr CAGR)
- 7.4%
- ROIC (10-yr avg)
- -844.0%
- Free cash flow (FY2025)
- -$17.6M
VVOS 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $17.4M | -$21.2M | -$2.07 | -$17.6M | -114.1% | -1861.1% |
| FY2024 | $15.0M | -$11.1M | -$1.11 | -$13.3M | -74.3% | -778.2% |
| FY2023 | $13.8M | -$13.6M | -$1.39 | -$12.7M | -125.3% | -837.4% |
| FY2022 | $16.0M | -$23.8M | -$3.24 | -$20.5M | -156.2% | -626.4% |
| FY2021 | $16.9M | -$20.3M | — | -$18.1M | -120.7% | -935.2% |
| FY2020 | $13.1M | -$12.1M | — | -$5.8M | -92.1% | -601.6% |
| FY2019 | $11.4M | -$10.8M | — | -$5.5M | -92.8% | -268.4% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Vivos Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Vivos Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -8.4% ROIC.
Vivos Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Vivos Therapeutics, Inc. is modeled at 7.4% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-41.47 per share.